Sleep Disorders News
-
MedSource Labs Corporate Wellness Tips: Digital Detox and Screen Time Management
In today’s digital age and remote work environments, the boundaries between work and personal life have become increasingly blurred. With the prevalence in our lives of smartphones, tablets, and laptops, employees are spending more time in front of screens than ever before. As executives, it’s our responsibility to recognize the impact of excessive screen time on our ...
-
Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Significantly Less Potential for Abuse Versus Tramadol and Oxycodone
Study evaluating human abuse potential demonstrates that the likeability of cebranopadol administered orally in nondependent recreational opioid users was significantly less as compared to immediate release (IR) formulations of either tramadol or oxycodone, suggesting a lower potential for abuse versus traditional C-II and C-IV opioids A first-in-class investigational analgesic uniquely ...
-
Signifier Medical Technologies’ eXciteOSA®, the only FDA-authorized daytime therapy for primary snoring and mild obstructive sleep apnea, demonstrates real-world adherence to treatment of over 80%
Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announced today the results of an analysis of real-world patient adherence data for its lead product, eXciteOSA. The data demonstrated that real-world patients in the US prescribed eXciteOSA, the first daytime therapy indicated to treat primary snoring and mild ...
-
Canaquest - Recent developments
Pharmaceutical: We are perfecting our CQ-001 Drug Candidate (CBD based IP formula) delivery system for Epilepsy in readiness for another Clinical Study for efficacy at the Ontario Brain Institute “OBI”……targeting September. Our first Clinical Study at OBI already achieved a 20% reduction in seizures……..we believe we can do better with our more concentrated ...
-
SoeMac user testimonials - better breathing
We’re always pleased to receive a testimonial from any of our SoeMac users. Here are just a few shared recently with us by people who have found that SoeMac helps them to breathe more easily. Celia - Breathing Neil, thankyou so much for servicing my SoeMac. I received it back this morning and will clean it regularly as per the instructions. I am so grateful, SoeMac has really helped with ...
By SoeMac
-
Citrine Medicine Announces Approval of Wakix (pitolisant) for Named Patient Program in China
The narcolepsy drug Wakix can now be prescribed to patients in China with urgent unmet medical needs BOSTON, Mass., and Boao, Hainan, China, May 07, 2021 – Citrine Medicine, a China-based rare disease therapeutics company, today announced that the narcolepsy therapy Wakix® (pitolisant) has been approved by the Health Commission and Medical Products Administration of Hainan Province ...
-
Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced biomarker data from the KALM-1 and KALM-2 clinical trials evaluating KORSUVA™ (difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus in patients undergoing ...
-
Neopharmed Gentili acquires Lormetazepam product portfolio to strengthen its neurology division
Neopharmed Gentili acquires rights in Italy and Japan to the historical brands Minias® and Noctamid® (Italy) and Evamyl® (Japan). The transaction allows Neopharmed Gentili to strengthen its portfolio in the neuro-psychiatric area with high value-added drugs for the treatment of insomnia. Neopharmed Gentili, an Italian pharmaceutical company controlled by Ardian in partnership ...
-
Lungpacer Medical, Inc. Presentations at American Thoracic Society Conference, Scheduled for May 2020, Philadelphia, Pennsylvania
An average of 14,000 pulmonary, critical care and sleep medicine clinicians and researchers from around the world attend the ATS multidisciplinary conference each year. Unfortunately, due to the COVID-19 global crisis the 2020 meeting has been cancelled. However, Lungpacer Medical, Inc. is pleased to announce that four preclinical abstracts were accepted for poster presentation, and one for ...
-
Nyxoah to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will be held virtually ...
By Nyxoah SA
-
The Irish News - Latest cash injection sees medical tech firm Neurovalens target US growth
Neurovalens has been boosted by £750,000 from the Growth Finance Fund to support the launch of a new sleep product in the USA later this year. In September the company, founded by Dr Jason McKeown in 2015 and which has already secured £4.6 million from a number of equity investors, was offered £1 million from Invest NI for its new research and development programme in a move ...
-
Belfast Newsletter - Health tech company creates 22 new jobs
Neurovalens, a global leader of neuro-technology products, is embarking on the development of a device for the treatment of obesity with £1m support from Invest NI. The technology is based on the neuro stimulation of specific areas of the brain responsible for influencing appetite and cravings. The company specialises in combining neuroscience and technology to tackle global health ...
-
Nyxoah Provides General Corporate Update
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today provided a general corporate update. 2021 Highlights Implanted first U.S. patient in the DREAM IDE pivotal study in December 2020; there are currently ...
By Nyxoah SA
-
Mojo Vision Partners With Fitness Brands to Elevate Sports and Fitness Experience and Performance via Its Smart Contact Lens
SARATOGA, Calif.--(BUSINESS WIRE)--Mojo Vision, the Invisible Computing Company, today announced strategic partnerships with leading sports and fitness brands to collaborate on next-generation user experiences that combine augmented reality, wearable technology and personal performance data. The companies will work together using Mojo's smart contact lens technology, Mojo Lens, to find unique ...
-
Nyxoah Announces Participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference on from November ...
By Nyxoah SA
-
Nyxoah appoints new CFO
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Loïc Moreau will join Nyxoah as CFO as of January 1, 2022. Loïc will join Nyxoah from GSK, where he held leadership roles in ...
By Nyxoah SA
-
Nyxoah Announces Participation in the Stifel 2021 Virtual Healthcare Conference
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021, ...
By Nyxoah SA
-
eXciteOSA® Daytime Sleep Apnea Therapy Device Surpasses 50,000 Patient Session Milestone
Signifier Medical Technologies Ltd, an innovator in the sleep-disordered breathing market, announced today that it has hit the 50,000 therapy session milestone with its innovative eXciteOSA® sleep device. Following FDA authorization and clearance for marketing in February 2021, eXciteOSA has been quickly adopted by physicians and patients alike. The first of its kind, eXciteOSA is a daytime ...
-
Nyxoah Announces CE-Mark Indication Approval to Treat Complete Concentric Collapse (CCC) Patients
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved the Company’s proposed indication for the Genio® system to treat patients with a Complete ...
By Nyxoah SA
-
Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the U.S. Food and Drug Administration (FDA) has granted the Genio® bilateral hypoglossal nerve stimulation system Breakthrough Device ...
By Nyxoah SA
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you